Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories

Fineline Cube Jun 30, 2026
Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Fineline Cube Jun 29, 2026
Company Legal / IP

JD Healthcare’s H1 2022 Financial Report Shows Strong Growth in Revenue and Profits

Fineline Cube Aug 26, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), reported robust financial results...

Company

Everest Medicines CEO Resigns as Trodelvy Sale Completed

Fineline Cube Aug 26, 2022

China-based biotech Everest Medicines (HKG: 1952) announced the resignation of CEO Dr. Kerry Blanchard, effective...

Company Deals

Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech

Fineline Cube Aug 26, 2022

Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B...

Company Deals

Lab Direct Raises USD 10M in Series A+ to Expand Digital Supply Chain Platform

Fineline Cube Aug 26, 2022

Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in...

Company Deals

Health Plus Receives Strategic Investment from Meinian Onehealth to Drive Healthcare Innovation

Fineline Cube Aug 26, 2022

Beijing-based Health Plus, a third-party digital managed healthcare service platform, has received strategic investment from...

Company Deals

Prismlab China Raises USD 29.1M in Series C for 3D Printing Expansion

Fineline Cube Aug 26, 2022

Shanghai-based 3D printing solution provider Prismlab China Ltd has raised RMB 200 million (USD 29.1...

Company Drug

Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company Drug

Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company

Novartis to Spin Off Sandoz, Focus on Innovative Drugs

Fineline Cube Aug 26, 2022

Swiss drugmaker Novartis announced plans to spin off its generic and biosimilar unit, Sandoz, to...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers

Fineline Cube Aug 26, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial...

Company

CStone Pharmaceuticals’ H1 2022 Revenue Jumps 229% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based CStone Pharmaceuticals (HKG: 2616) reported RMB 262 million (USD 49.4 million) in revenue for...

Company

Innovent Biologics’ H1 2022 Revenue Rises 15.3% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) reported RMB 2.24 billion (USD 326.4 million) in revenue...

Company

Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales

Fineline Cube Aug 25, 2022

China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for...

Company Drug

Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases

Fineline Cube Aug 25, 2022

Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...

Company Deals

eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership

Fineline Cube Aug 25, 2022

Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million...

Company Drug

Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial

Fineline Cube Aug 25, 2022

Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...

Company Deals

Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms

Fineline Cube Aug 25, 2022

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...

Company Policy / Regulatory

NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall

Fineline Cube Aug 25, 2022

The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...

Posts pagination

1 … 654 655 656 … 688

Recent updates

  • Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed – RenNano Platform Cleared of Antibody Technology Violations
  • Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery
  • Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories
  • AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
  • Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Legal / IP

Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed – RenNano Platform Cleared of Antibody Technology Violations

Company Medical Device

Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery

Company Drug

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories

Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.